Product Update

RNS Number : 5202U

Hikma Pharmaceuticals Plc

18 October 2010

 



Update on Hikma's US Generics Business

London, 18 October 2010 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ DUBAI: HIK)("Hikma"), the fast growing multinational pharmaceutical group, announces that the dispute between West-Ward Pharmaceutical Corp., Hikma's US agent and wholly-owned subsidiary, and Mutual Pharmaceutical Company, Inc. relating to the sale of oral colchicine tablets has been resolved to the parties' mutual satisfaction.  West-Ward has discontinued its sales of oral colchicine until approval of its New Drug Application by the U.S. Food and Drug Administration.

Hikma reconfirms its previously stated guidance of at least 20% revenue growth for its US Generics business for the full year 2010 and continues to expect its core US Generics business to perform well in 2011.

ENDS

Enquiries

Hikma Pharmaceuticals PLC	[phone]
Susan Ringdal, Investor Relations Director
Financial Dynamics
Ben Atwell	[phone]
Julia Phillips	[phone]
Matthew Cole

About Hikma

Hikma Pharmaceuticals PLC is a fast growing global pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2009, Hikma achieved revenues of  $637 million and profit attributable to shareholders of $78 million.  For news and other information, please visit www.hikma.com.

 

END

 

 

PRLLFFLIISLDLII